Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics

Managing Your Screenings and Surveillance

At a Glance

PALB2 carriers generally need earlier, more intensive breast screening, while pancreatic surveillance depends on personal and family history. Routine ovarian screening is usually not recommended without symptoms; discuss risk-reducing surgery and report warning signs promptly.

Now that you know your PALB2 status, your medical care shifts from general wellness to specialized surveillance. The goal of this screening is twofold: to detect any changes at their earliest, most treatable stage and to provide you with peace of mind. Your specific schedule is based on consensus from major medical organizations like the National Comprehensive Cancer Network (NCCN) [1].

Breast Cancer Screening

For women and people with female breast tissue, the screening guidelines for PALB2 carriers are intensive and aim to catch breast cancer early [2].

  • Breast MRI: You will typically begin annual contrast-enhanced breast MRI between the ages of 30 and 35, or 5 to 10 years before the earliest breast cancer diagnosis in your family [1]. MRI is highly sensitive and is excellent at finding small changes in dense breast tissue [3].
  • Mammography: You will also begin annual mammograms (specifically 3D tomosynthesis) starting around age 30 to 40 depending on the specific guideline and your personal risk [3][4].
  • Staggered Schedule: Many specialists offer a “staggered” schedule—for example, having your MRI in January and your mammogram in July—so that your breasts are being professionally imaged every six months. This is an optional coordination strategy, not a strict requirement [5][6].
  • Clinical Exams: A healthcare provider should perform a clinical breast exam every 6 to 12 months [2].

For male carriers: Men with a PALB2 variant have a different, less intensive approach. You should discuss performing self-exams and having clinical breast exams during routine doctor visits, as male breast cancer risk, while elevated, is much lower than female risk [7].

Pancreatic Cancer Screening

Pancreatic screening guidelines vary, and you should have an individualized discussion with your care team about whether you qualify [8].

  • Who Qualifies: Most guidelines recommend pancreatic screening if you have a PALB2 mutation and a family history of the disease. Some guidelines specify a first-degree relative (parent, sibling, child), while others include second-degree relatives or suggest considering screening regardless of family history [9][10].
  • When to Start: Screening usually begins at age 50, or 10 years earlier than the age your youngest relative was diagnosed, whichever comes first [11][9].
  • The Methods: Screening is performed annually using specialized imaging: either an Endoscopic Ultrasound (EUS) or a high-resolution MRI/MRCP [11][9]. These tests should be performed at high-volume centers with expertise in high-risk surveillance [2].

Why Ovarian Screening is Different

While PALB2 increases the risk of ovarian cancer, routine screening with transvaginal ultrasound (TVUS) or CA-125 blood tests is typically not recommended for women who do not have symptoms [2][12].

Research has shown that these screening tools are not effective at reducing the number of deaths from ovarian cancer [13]. They often miss early-stage disease and have a high rate of false positives, which can lead to unnecessary and invasive surgeries [14][15]. Instead of screening, most experts recommend discussing risk-reducing surgery (removal of the fallopian tubes and ovaries) once you have finished having children [2][12].

Red Flags: When to Call Your Doctor

Screening is intended for people without symptoms. If you notice any of the following “red flag” symptoms, do not wait for your next scheduled screening; contact your care team promptly for a diagnostic evaluation, even if a recent screening test was normal.

Breast Red Flags [16][17]:

  • A new, firm, or fixed lump in the breast or underarm.
  • Skin changes, such as dimpling, puckering, or redness that looks like an orange peel (peau d’orange).
  • Nipple retraction (turning inward) or unusual nipple discharge.

Pancreatic Red Flags [18]:

  • Jaundice: Yellowing of the skin or the whites of the eyes (this requires urgent same-day evaluation).
  • Unexplained weight loss or a significant loss of appetite.
  • New-onset mid-back pain or upper abdominal pain that does not go away.

Ovarian Red Flags [15]:

  • New, persistent, or worsening abdominal bloating or feeling “full” very quickly after eating over roughly two weeks or more.
  • Pelvic or abdominal pain that occurs almost daily.
  • Urgent or frequent need to urinate that is a new change for you.

Having these symptoms does not mean you have cancer, but for a PALB2 carrier, they require prompt medical investigation to rule it out [16].

Common questions in this guide

When should I start breast MRI and mammograms if I have a PALB2 variant?
For women and people with female breast tissue, annual contrast-enhanced breast MRI commonly starts at age 30 to 35, or 5 to 10 years before the earliest breast cancer in the family. Annual mammography, often with 3D imaging, is generally added around age 30 to 40. Your clinician should personalize the timing to your family history and other risk factors.
Do all people with a PALB2 mutation need pancreatic cancer screening?
Not necessarily. Many recommendations focus on people who have a PALB2 variant and a family history of pancreatic cancer, while some experts consider screening more broadly. Ask your care team whether your history qualifies and whether regular screening is available at an experienced high-volume center.
What tests are used to screen for pancreatic cancer in PALB2 carriers?
When pancreatic screening is recommended, it is usually done once a year with either an endoscopic ultrasound, which uses a flexible tube to create ultrasound images from inside the digestive tract, or a high-resolution MRI/MRCP scan. Screening often starts at age 50 or 10 years before the youngest pancreatic cancer diagnosis in the family, whichever comes first. These tests should be performed at high-volume centers with relevant expertise.
Should people with a PALB2 variant and no symptoms get ovarian cancer screening?
Routine transvaginal ultrasound or CA-125 blood testing is generally not recommended for people without symptoms because these tests have not been shown to reduce ovarian cancer deaths and can produce false alarms. False-positive results may lead to unnecessary invasive procedures. Discuss risk-reducing surgery to remove the fallopian tubes and ovaries after childbearing is complete.
Is it helpful to alternate my PALB2 breast MRI and mammogram?
Some specialists schedule the two annual breast tests about six months apart, such as an MRI in January and a mammogram in July. This staggered approach keeps imaging spread through the year, but it is an optional way to coordinate care rather than a strict requirement.
What symptoms should prompt a PALB2 carrier to call the doctor?
Contact your care team promptly for a new breast lump, skin dimpling or redness, nipple inversion or unusual discharge, new or persistent bloating, early fullness, abdominal or pelvic pain, or urinary urgency or frequency. Yellowing of the skin or eyes, called jaundice, needs same-day evaluation. These symptoms do not prove cancer, but they should be assessed rather than waiting for the next routine screening.

Get notified when new evidence is published on PALB2-related cancer predisposition.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.

    Hudson L, Gower N, Lenarcic S, et al.

    Annals of surgical oncology 2020; (27(7)):2248-2254 doi:10.1245/s10434-019-08191-0.

    PMID: 31974710
  2. 2

    Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Tischkowitz M, Balmaña J, Foulkes WD, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(8)):1416-1423 doi:10.1038/s41436-021-01151-8.

    PMID: 33976419
  3. 3

    Risk-reducing surgery in PALB2 mutations carriers with breast cancer: a case series and literature review.

    Masanam MK, Pitcher CW, Sogunro O, et al.

    Translational breast cancer research : a journal focusing on translational research in breast cancer 2022; (3()):37 doi:10.21037/tbcr-22-33.

    PMID: 38751533
  4. 4

    Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.

    Lowry KP, Geuzinge HA, Stout NK, et al.

    JAMA oncology 2022; (8(4)):587-596 doi:10.1001/jamaoncol.2021.6204.

    PMID: 35175286
  5. 5

    Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

    Esserman LJ, Fiscalini AS, Naeim A, et al.

    JAMA 2026; (335(9)):763-774 doi:10.1001/jama.2025.24784.

    PMID: 41385349
  6. 6

    Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.

    Shieh Y, Heise RS, Madlensky L, et al.

    JAMA oncology 2026; (12(8)):875-880 doi:10.1001/jamaoncol.2026.2091.

    PMID: 42218736
  7. 7

    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

    Yang X, Leslie G, Doroszuk A, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(7)):674-685 doi:10.1200/JCO.19.01907.

    PMID: 31841383
  8. 8

    Pancreatic Cancer Surveillance: Who, When, and How.

    Dudley B, Brand RE

    Current treatment options in gastroenterology 2019; (17(4)):681-691 doi:10.1007/s11938-019-00247-0.

    PMID: 31761968
  9. 9

    AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.

    Aslanian HR, Lee JH, Canto MI

    Gastroenterology 2020; (159(1)):358-362 doi:10.1053/j.gastro.2020.03.088.

    PMID: 32416142
  10. 10

    Outcomes of pancreatic cancer surveillance among high-risk individuals at a tertiary care academic center.

    Lee AA, Twoy A, Siddappa P, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2026; (26(5)):719-723 doi:10.1016/j.pan.2026.06.006.

    PMID: 42399188
  11. 11

    Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

    Goggins M, Overbeek KA, Brand R, et al.

    Gut 2020; (69(1)):7-17 doi:10.1136/gutjnl-2019-319352.

    PMID: 31672839
  12. 12

    Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.

    Liu YL, Breen K, Catchings A, et al.

    JCO oncology practice 2022; (18(3)):201-209 doi:10.1200/OP.21.00382.

    PMID: 34582274
  13. 13

    Ovarian Cancer Prevention and Screening.

    Menon U, Karpinskyj C, Gentry-Maharaj A

    Obstetrics and gynecology 2018; (131(5)):909-927 doi:10.1097/AOG.0000000000002580.

    PMID: 29630008
  14. 14

    Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.

    , Grossman DC, Curry SJ, et al.

    JAMA 2018; (319(6)):588-594 doi:10.1001/jama.2017.21926.

    PMID: 29450531
  15. 15

    Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.

    Obstetrics and gynecology 2017; (130(3)):e146-e149 doi:10.1097/AOG.0000000000002299.

    PMID: 28832487
  16. 16

    Clinically Malignant Breast Lesion in an Adolescent Girl: A Case Report.

    Sosnowska-Sienkiewicz P, Mańkowski P

    Clinics and practice 2021; (11(3)):435-440 doi:10.3390/clinpract11030058.

    PMID: 34287288
  17. 17

    Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides.

    Yaghoobi R, Talaizade A, Lal K, et al.

    The Journal of clinical and aesthetic dermatology 2015; (8(8)):47-51.

    PMID: 26345728
  18. 18

    When a metastatic breast cancer is mimicking a pancreatic cancer: case report and review of the literature.

    Derouane F, Yombi JC, Baurain JF, et al.

    Acta clinica Belgica 2020; (75(4)):301-307 doi:10.1080/17843286.2019.1607990.

    PMID: 31035903

This page is for informational purposes only and does not constitute medical advice. Your care team should tailor PALB2 screening, surveillance, and risk-reducing options to your personal and family history.